



The TIMI Trials

TIMI 11B

OBJECTIVE: To evaluate the safety and efficacy of subcutaneous enoxaparin compared with unfractionated heparin for the treatment of patients presenting with unstable angina or non-Q-wave myocardial infarction.

1. Antman EM, McCabe C, Gurfinkel E, Turpie AGG, Bernink PJLM, Salein D, Bayes de Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E, for the TIMI 11B Investigators. Enoxaparin prevents death in cardiac ischemia events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI 11B) Trial. *Circulation* 1999;100:1593-1601.
2. Antman EM. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo- controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators. *Am Heart J* 1998;135:S353-60.
3. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E, for the TIMI 11B and ESSENCE Investigators. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. *Circulation* 1999;100:1602-1608.
4. Antman EM, Cohen M, Bernink PJLM, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. *JAMA* 2000; 284: 835-842.
5. Bozovich G, Gurfinkel E, Antman EM, McCabe CH, Mautner B, for the TIMI 11B Investigators. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. *Am Heart J* 2000; 140: 637-642.
6. Cohen M, Antman EM, Gurfinkel E, Turpie AGG, Furst J, Bigonzi F, Radley D. Impact of enoxaparin on low molecular weight heparin in patients with Q-wave myocardial infarction. *Am J Cardiol* 2000; 86: 553-556.
7. Morrow DA, Antman EM, Tanasijevic M, Rifai N, de Lemos JA, McCabe CH, Cannon CP, Braunwald E. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI 11B substudy. *J Am Coll Cardiol* 2000; 36: 1812-7.
8. Morrow DA, Rifai N, Tanasijevic M, Wybenga DR, de Lemos, JA, Antman EM. Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a thrombolysis in myocardial infarction (TIMI) 11B substudy. *Clinical Chemistry* 2000; 46: 453-460.
9. Cohen M, Antman EM, Gurfinkel EP, Radley D. Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups. *J Thromb Thrombolysis* 2001;12:199-206.
10. Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? *Am Heart J* 2001;142:590-3.
11. Holper EM, Antman EM, McCabe CH, Premmereur J, Gurfinkel E, Bernink PJ, Turpie AG, Bayes de Luna A, Lablanche JM, Fox KM, Salein D, Radley DR, Braunwald E. A simple, readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction. *Am J Cardiol* 2001;87:1008-10
12. Santopinto J, Gurfinkel EP, Torres V, Marcos E, Bozovich GE, Mautner B, McCabe CH, Antman EM. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. *Am Heart J* 2001; 141: 566-572.

13. Inverso SM, Cohen M, Antman EM, Spinler SA, for the ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin (UH) versus enoxaparin(E) in obese patients and patients with renal impairment: analysis from ESSENCE and TIMI 11B studies. *J Am Coll Cardiol* 2001; 37(suppl A): 365A.
14. Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. *Eur Heart J* 2002;23:308-14.
15. Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. *Am Heart J* 2002;143:753-9.
16. Cohen M, Antman EM, Murphy SA, Radley D. Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes. *Am Heart J* 2002;143:63-9.
17. Cohen M, Antman EM. Superiority of enoxaparin over unfractionated heparin for the treatment of acute coronary syndromes. *Pharmacotherapy* 2002;22:542-6; discussion 546-50.
18. Fox KA, Antman EM, Cohen M, Bigonzi F. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. *Am J Cardiol* 2002;90:477-82.
19. Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, Braunwald E. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. *Am J Cardiol* 2002;89:463-5.
20. Sabatine MS, McCabe CH, Morrow DA, Giugliano RP, de Lemos JA, Cohen M, Antman EM, Braunwald E. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. *Am Heart J* 2002;143:966-70.
21. DeLemos JA, Morrow DA, Gibson CM, Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald E. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. *J Am Coll Cardiol* 2002;40:238-244.
22. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM for the ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. *American Heart Journal* 2003;146:33-41.
23. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. A systematic overview of efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes. *JAMA* 2004;292:89-100.
24. Yeh RW, Wiviott SD, Giugliano RP, Morrow DA, Shui A, Qin J, Scirica B, Bradner JE, Jang IK, Gibson CM, Antman EM. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. *Am J Cardiol* 2007;100:1734-8